



THE UNIVERSITY *of* EDINBURGH

Edinburgh Research Explorer

Fine Tuning of Craniofacial Morphology by Distant-Acting Enhancers

Citation for published version:

Attanasio, C, Nord, AS, Zhu, Y, Blow, MJ, Li, Z, Liberton, DK, Morrison, H, Plajzer-Frick, I, Holt, A, Hosseini, R, Phouanavong, S, Akiyama, JA, Shoukry, M, Afzal, V, Rubin, EM, FitzPatrick, DR, Ren, B, Hallgrímsson, B, Pennacchio, LA & Visel, A 2013, 'Fine Tuning of Craniofacial Morphology by Distant-Acting Enhancers', *Science*, vol. 342, no. 6157, 1241006. <https://doi.org/10.1126/science.1241006>

Digital Object Identifier (DOI):

[10.1126/science.1241006](https://doi.org/10.1126/science.1241006)

Link:

[Link to publication record in Edinburgh Research Explorer](#)

Document Version:

Peer reviewed version

Published In:

Science

Publisher Rights Statement:

Published in final edited form as:
Science. Oct 25, 2013; 342(6157): 1241006.
doi: 10.1126/science.1241006

General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.





Published in final edited form as:

Science. 2013 October 25; 342(6157): 1241006. doi:10.1126/science.1241006.

Fine Tuning of Craniofacial Morphology by Distant-Acting Developmental Enhancers

Catia Attanasio¹, Alex S. Nord¹, Yiwen Zhu¹, Matthew J. Blow², Zirong Li^{3,4}, Denise K. Liberton⁵, Harris Morrison⁶, Ingrid Plajzer-Frick¹, Amy Holt¹, Roya Hosseini¹, Sengthavy Phouanenvong¹, Jennifer A. Akiyama¹, Malak Shoukry¹, Veena Afzal¹, Edward M. Rubin^{1,2}, David R. FitzPatrick⁶, Bing Ren³, Benedikt Hallgrímsson⁵, Len A. Pennacchio^{1,2}, and Axel Visel^{1,2,*}

¹Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA

²DOE Joint Genome Institute, Walnut Creek, CA

³Ludwig Institute for Cancer Research, and Department of Cellular and Molecular Medicine, University of California, San Diego School of Medicine, 9500 Gilman Drive, La Jolla, CA

⁵Dept. of Cell Biology & Anatomy, McCaig Bone and Joint Institute and the Alberta Children's Hospital Research Institute, University of Calgary, Canada

⁶MRC Human Genetics Unit, MRC Institute for Genetic and Molecular Medicine, University of Edinburgh, Edinburgh EH4 2XU, UK

Abstract

The shape of the human face and skull is largely genetically determined, but the genetic drivers of craniofacial morphology remain poorly understood. Here we used a combination of epigenomic profiling, *in vivo* characterization of candidate enhancer sequences in transgenic mice, and targeted deletion experiments to examine the role of distant-acting enhancers in craniofacial development. We identified complex regulatory landscapes, consisting of enhancers that drive a remarkable spatial complexity of developmental expression patterns. Deletion of individual craniofacial enhancers from the mouse genome resulted in significant alterations of craniofacial shape, demonstrating their functional importance in defining face and skull morphology. These results demonstrate that enhancers play a pervasive role in mammalian craniofacial development and suggest that enhancer sequence variation contributes to human facial morphology.

*Correspondence to: A.V., avisel@lbl.gov.

⁴Present address: EMD Millipore, 28820 Single Oak Drive, Temecula, CA 92590, USA

Supplementary Materials:

www.sciencemag.org

Material and methods

Supplementary online text

Figs. S1–S6

Tables S1–S6

Movies S1–S20

References (62–91)

Introduction

The shape of the face is one of the most distinctive features among humans, and differences in facial morphology have substantial implications in many areas, including social interaction, psychology, forensics, and clinical genetics (1–3). The resemblance of facial shapes within families in general, and between monozygotic twins in particular, suggests a major contribution of genetic factors to craniofacial morphology (4–6). Many protein-coding genes whose disruption causes major aberrations of craniofacial morphology are known. This includes pathological dysmorphologies of the face itself, such as clefts of the lip or palate, as well as distinctive facial features associated with genetic syndromes that are indicative of associated pathologies in other organ systems (7–14). In contrast to these disease-associated genes, the genetic drivers of normal craniofacial variation remain poorly understood. A small number of candidate genes have been implicated in variation of craniofacial shape through genome-wide association studies, but collectively they explain only a minute fraction of the morphological variation observed in human populations (15–17). It remains a central question how complex traits such as the overall shape of the face can be modulated in quantitatively subtle ways, while avoiding the often severe consequences associated with protein-coding mutations (18).

Recent observations of large numbers of distant-acting transcriptional enhancers in mammalian genomes (19, 20) raise the possibility that these sequences play a significant role in the development of structures like the craniofacial complex. Enhancers typically have highly restricted *in vivo* activity patterns and often control the expression of their target genes in a modular fashion, where different enhancers activate the expression of the same gene in different cell types, anatomical regions, or at different developmental time points (21). In principle, such complex arrays of enhancers acting on individual genes may provide a general mechanism for the independent fine tuning of distinct aspects of gene expression in different developmental processes, which in turn may affect specific phenotypic traits including facial shape (22). This model is consistent with the extensive studies of the genes and gene regulatory networks involved in the development of the neural crest, a cell population contributing to multiple tissues including facial bone and cartilage (23). In-depth studies of individual genes involved in neural crest development (e.g., (24–26)), as well as genome-wide studies of regulatory sequences active in human neural crest cells (27) support that many genes involved in craniofacial development are associated with complex regulatory architecture. However, owing to the lack of systematic genome-scale *in vivo* studies, the genomic location and spatiotemporal activity patterns of such craniofacial *in vivo* enhancers remain poorly understood. In the present study we use an epigenomic method on whole face tissue to explore the genome-wide landscape of craniofacial enhancers, and study their involvement in defining craniofacial morphology using large-scale transgenic reporter assays and enhancer knockout studies in mice.

Identification of *in vivo* Craniofacial Enhancers

To identify craniofacial developmental enhancers on a genome-wide scale, we performed ChIP-seq analysis on mouse embryonic day (e) 11.5 facial tissue with the enhancer-associated p300 protein (21) (fig. 1). At this developmental time point, key events of

craniofacial development are in progress, including growth and morphogenetic processes affecting the size, shape and structure of all major craniofacial prominences (28, 29). All major facial subregions were included in this tissue preparation (30), building on the previously described efficiency of this inclusive approach to identify enhancers with both broad and tightly confined patterns in subregions of developing embryonic structures (31, 32).

Enrichment analysis identified 4,399 distal candidate enhancers genome-wide, defined as regions that showed significant p300 binding in craniofacial tissue and were at least 2.5kb from known transcription start sites (fig. 2, table S1 and S2). Candidate enhancers were located at a median distance of 44kb from the nearest transcript start site, with 38.4% in introns of genes and 54.7% located in non-coding regions outside of genes (intergenic). The majority of candidate enhancers also showed evidence of significant evolutionary constraint (87.5%, table S1) and had unique orthologous sequences in the human genome (96.7%). Unbiased ontology analysis (33) revealed that candidate craniofacial enhancers are enriched near genes that are known to cause craniofacial phenotypes when deleted in mouse models or mutated in humans (table 1). Candidate craniofacial enhancers were also significantly enriched at loci implicated in human craniofacial traits and birth defects through genome-wide association studies (fig. S1). These observations are consistent with a role of the identified enhancer candidate sequences in the regulation of genes with known roles in craniofacial development. Taken together, these results suggest that thousands of distant-acting enhancers are involved in orchestrating the genome-wide gene expression landscape during craniofacial development.

Large-scale Transgenic Analysis of Craniofacial Enhancers

ChIP-seq performed directly on craniofacial tissues provided a genome-wide catalogue of sequences that are likely to be active *in vivo* enhancers during craniofacial development at e11.5. However, this approach does not provide direct insight into the exact activity patterns of individual candidate enhancer sequences. To examine craniofacial enhancer activity patterns in detail, we used transgenic enhancer reporter assays in mice, coupled to high-resolution three-dimensional mapping of LacZ reporter activities by optical projection tomography (OPT) (fig. 1 and (30)) (41, 42). Since many, but not all *in vivo* enhancers can be identified by p300 binding (43), we also considered sequence conservation (41) and proximity to genes or loci with a known role in craniofacial development as additional criteria in the selection of candidate sequences. In total, we tested 205 candidate sequences in transgenic mice, with the majority (123 or 60%) located within or near regions associated with craniofacial development through experimental, genetic or genome-wide association studies (see table S3 for properties of all tested candidate sequences). Each candidate enhancer sequence was coupled to a minimal promoter and used to generate multiple transgenic embryos by pronuclear injection (30). Only patterns that were independently observed in at least three different embryos were considered reproducible. In total, 121 of 205 tested sequences showed reproducible reporter gene expression in at least one craniofacial structure. We further extended the set of *in vivo* characterized craniofacial enhancers by re-examining data from previously described large-scale enhancer screens not specifically targeted at craniofacial enhancer discovery (21, 31, 32, 41, 44–46), providing an

additional 75 craniofacial enhancers (table S3). Transgenic results for all 196 craniofacial enhancers identified or re-examined in this study are available through the Vista Enhancer Browser (<http://enhancer.lbl.gov>) or the NIDCR FaceBase consortium web site (<http://facebase.org>) (47).

To gain higher-resolution insight into the three-dimensional activity patterns of craniofacial enhancers in the context of developing embryos, we used optical projection tomography (OPT). In total, representative embryos for 55 craniofacial enhancers, including 48 that were newly identified in this study, were analyzed by OPT. Selected examples of three-dimensional views are provided as supplementary movies (movies S1–S11). More comprehensive OPT data collections can be interactively explored through a dedicated viewer at the NIDCR FaceBase database (see fig. S2) (47). Examination of this large set of *in vivo*-validated and characterized craniofacial enhancers highlights several salient features and resulting potential applications of these data sets, which we will describe using selected examples. Specifically, this collection of enhancers 1) identifies a remarkable diversity of enhancer activity patterns, highlighting the regulatory complexity of the genetic code; 2) enables the dissection of the regulatory landscapes of individual genes known to be involved in craniofacial development; 3) provides a starting point for the mechanistic exploration of genomic intervals implicated in craniofacial development through genome-wide association studies.

Diversity of Patterns

To illustrate the reproducibility and diversity of craniofacial activity patterns identified in transgenic embryos, selected examples of enhancers identified in this study are shown in fig. 3A. For all craniofacial prominences (medial nasal, lateral nasal, maxillary, and mandibular), structure-specific active enhancers were identified (see fig. 3A and S4A for a schematic view of the e11.5 mouse face). In depth analysis of craniofacial activity patterns through the combined use of whole-mount LacZ staining and OPT imaging revealed that in many cases only subregions of these structures were reproducibly targeted by an enhancer. For example, enhancer mm387 drives expression in the anterior part of the maxillary prominence while enhancer mm458 is restricted to a posterior ventral region (fig. 3B, top). Similar region-specific activities are observed in other facial substructures such as the nose, where enhancer mm933 is active in the medial nasal prominence, while the activity of enhancer mm426 is confined to the lateral nasal prominence (fig. 3B, top). OPT scans of whole-mount embryos provide additional spatial information about enhancer activity pattern by capturing the activity signal in internal embryonic structures (fig. 3B, bottom). These data highlight the complexity, diversity, and spatially highly restricted activity patterns of distant-acting enhancer sequences active during craniofacial development.

Regulatory Landscapes of Craniofacial Genes

Systematic screening of individual genomic loci via ChIP-seq followed by transgenic characterization enables functional dissection of the distant-acting enhancer landscapes of individual genes with known roles in craniofacial development. As an example, mouse *Msx1* and human *MSX1* have been extensively studied for their role in craniofacial development

(supplementary online text and (48)). *Msx1* is surrounded by several hundred kilobases of non-coding DNA, which renders the search for distant-acting enhancers by tiling approaches challenging. Transgenic testing of seven candidate sequences identified by ChIP-seq and located up to 235kb away from the *Msx1* transcription start site resulted in the identification of five distinct craniofacial enhancers potentially regulating its expression (fig. 4A). At e11.5, each of these enhancers drove patterns that partially recapitulated the endogenous *Msx1* RNA expression. For instance, *Msx1* activity in the second branchial arch and in the maxillary process of the e11.5 embryo is recapitulated by the combined activity of two separate enhancers located at 1kb and 235kb upstream of the promoter (mm426 and hs746, fig. 4A). These observations support the notion that complex spatial expression patterns of key developmental genes are driven by modular arrays of distant-acting enhancers (49) and highlights the potential of enhancers to provide a mechanism for fine tuning of *in vivo* gene expression patterns.

Craniofacial Enhancers within Disease-Associated Intervals

To illustrate the utility of these enhancer datasets in the follow-up of genome-wide association, population scale sequencing, and candidate locus studies, 50 candidate enhancers mapping to intervals implicated in craniofacial morphology or orofacial birth defects through human genetic studies were included in the transgenic assays (see table S3). Trait-associated variants that map to non-coding genome regions or are not linked to any protein-altering variants are a common challenge in the interpretation of such genetic studies. A prototypical example is the gene desert at human chromosome 8q24. A 640kb region in this interval is devoid of protein-coding genes, but is a major susceptibility locus for cleft palate with a calculated population attributable risk of 41% (35, 52, 53) and is significantly linked to normal variation in several facial morphology traits (16). We identified four craniofacial enhancer candidate sequences in this risk interval, two of which drive reproducible craniofacial reporter activity at e11.5 in transgenic mice (fig. 4B). As a second example, we examined the 1p22 locus. In this interval, markers located near and within the *ABCA4* gene are associated with an increased risk for cleft palate, but it remains unclear whether these variants are linked to deleterious protein-coding mutations of *ABCA4* (36, 54). Based on RNA expression data the neighboring gene *ARHGAP29*, rather than *ABCA4* itself, has been proposed to be causatively involved in craniofacial development (55). However, *ARHGAP29* falls outside the genomic boundaries of the risk-associated linkage block. By scanning the region comprising these two genes for possible associated enhancers, we identified a human-mouse conserved sequence in the first intron of *Abca4* that drove highly reproducible reporter activity in the facial midline, a pattern reminiscent of *Arhgap29* RNA expression, suggesting that this enhancer may drive expression of *Arhgap29* during craniofacial development (fig. 4C and movie S10) (56). A causative effect of sequence or copy number variants in these particular enhancers on craniofacial morphology remains to be demonstrated, furthermore we cannot exclude the existence of additional enhancer sequences at these loci that were not captured in the present screen. These possible limitations notwithstanding, our results illustrate the utility of collections of validated enhancers as starting points for the mechanistic interpretation of human genetic studies by linking functional genomic and human genetic data sets.

Targeted Deletions of Craniofacial Enhancers

The existence of large numbers of distant-acting enhancers with precise tissue-specific activities during craniofacial development raises the question of their functional impact on craniofacial morphology through the regulation of their respective target genes. To examine such contributions in more detail, we selected three enhancers with highly reproducible craniofacial activity patterns and explored their functions through targeted deletions in mice (fig. 1). The three enhancers, termed hs1431 (near *Snai2*), hs746 (near *Msx1*) and hs586 (near *Isl1*), were chosen based on their association with known craniofacial genes (7, 57, 58) (see supplementary online text), the robustness of their activity patterns, and the absence of additional known enhancers with overlapping activity near the same gene. Furthermore, the *in vivo* activity patterns driven by these enhancers partially recapitulate the known expression patterns of their presumptive target genes (fig. 4A and fig. S3). The enhancers were intentionally chosen from different, functionally unrelated loci in order to provide a representative sample of the genome-wide enhancer data set, rather than an in-depth exploration of a single gene or pathway. All selected enhancers are located at a very long distance from their respective target genes (350kb, 235kb and 190kb respectively) and are active in the craniofacial complex through multiple stages of embryonic development (fig. 4A, fig. S3, fig. 5 and movies S1–S9).

To test if these enhancers play a role in modulating craniofacial morphology, we created three separate mouse lines carrying deletion alleles for each of the three enhancers using a standard homologous recombination strategy in embryonic stem cells (30). Mice homozygous for any of the three enhancer deletions do not display gross craniofacial malformations or other obvious deficiencies. To evaluate the effect of each enhancer deletion on the expression of the presumptive target genes (*Snai2*, *Msx1* and *Isl1*), we used quantitative RT-PCR to measure transcript levels in different craniofacial structures of individual wild-type and enhancer deletion embryos (littermates) at e11.5 and e13.5 (fig. 6 and fig. S4). Depending on time-point and substructure, we observed up to 3.9-fold down-regulation ($P=4e-05$) of *Snai2* in homozygous Δ hs1431 embryos, 1.5-fold down-regulation ($P=0.015$) of *Msx1* in Δ hs746 and 1.3-fold down-regulation ($P=0.04$) of *Isl1* in Δ hs586 (fig. 6C, D and fig. S4E). Notably, in all cases the changes in transcript levels of the respective target gene were confined to subregions in which the enhancer was active. However, not all subregions with enhancer reporter activity showed significant down-regulation of the target gene. These observations raise the possibility of partial functional redundancy between the enhancers studied here and overlapping regulatory activities from gene promoters or additional distant-acting enhancers that were not captured in our genome-wide screen. Regardless of the presence of possible additional regulatory sequences in these genome intervals, these results provide direct evidence for the requirement of enhancers for normal gene expression during craniofacial development.

To examine if the deletion of these enhancers had a significant impact on craniofacial development beyond expression phenotypes, we compared mouse skulls from wild-type and enhancer deletion mice at eight weeks of age. Since it is challenging to quantify possible differences in craniofacial morphology by visual observation alone, we used micro-computed tomography (micro-CT) to obtain accurate three-dimensional measurements of

the skulls. Three cohorts, each consisting of at least 30 mice homozygous for a deletion of one of the three enhancers, were compared to a cohort of 44 wild-type littermates. Micro-CT reconstructions of each mouse head were measured using 54 standardized skeletal landmarks (fig. S5). The cohorts of wild-type and enhancer deletion mice were compared using canonical variate analysis (CVA) to identify possible changes in craniofacial morphology resulting from the enhancer deletions (fig. 7). Procrustes ANOVA ($F=12.0$, $p<0.0001$) and MANOVA (Pillai's Trace 2.5, $p<0.0001$) tests both showed that enhancer deletion genotypes were significantly associated with alterations of craniofacial shape. All individual pair-wise permutation tests (Procrustes distances) between wild-type and enhancer deletion lines revealed significant differences (table S4), with the most pronounced differences observed for $\Delta hs1431$ and $\Delta hs746$ (both $P<0.0001$ compared to wild-type). Differences between wild-type, $\Delta hs1431$, and $\Delta hs746$ mice were also significant after Bonferroni adjustment for the 6 pairwise comparisons between groups. The largest magnitude of effect on shape was observed for $\Delta hs1431$, followed by an intermediate quantitative effect for $\Delta hs746$ (fig. 7B), whereas possible changes in $\Delta hs586$ were mildest and sub-significant after correction for multiple hypothesis testing. These results mirror the magnitude of expression phenotypes, which were most pronounced in $\Delta hs1431$, followed by intermediate changes in $\Delta hs746$ and only a limited expression phenotype observed in $\Delta hs586$ (fig. 6 and fig. S4). In summary, these results demonstrate a significant effect of enhancer deletions on craniofacial morphology.

Each enhancer deletion causes a distinct set of differences compared to wild-type morphology. This is evident from the CVA, where the first three canonical variates (CV1-CV3) most clearly separate wild-type mice from $\Delta hs1431$, $\Delta hs746$, and $\Delta hs586$ respectively (fig. 7). Each enhancer deletion produces phenotypic effects that are not confined to a single feature, but involve multiple regions of the skull (fig. 7C, movies S12–S20). For example, deletion of $hs1431$ results in an increase in facial length, a relative increase in the width of the anterior neurocranium and a shortening of the anterior cranial base. In contrast, $\Delta hs746$ results in a shortening of the face, a widening of the posterior neurocranium, a narrowing of the palate and shortening of the cranial base. While both $\Delta hs1431$ and $\Delta hs746$ have significant effects on facial morphology in structures derived from regions with enhancer activity at $e11.5$ and $e13.5$ (fig. 6), there are also changes in other parts of the skull. These correlated patterns of change are consistent with numerous studies demonstrating that cranium development is a highly integrated process, and that variation of the skull is structured by complex interactions between the growing chondrocranium, neurocranium and other nearby tissues (59, 60). Regardless of the precise molecular pathways and developmental mechanisms that underlie the morphological changes observed upon deletion of these enhancers, these results demonstrate a direct role of distant-acting enhancers in the development of craniofacial shape in mammals. The observation of significant, but non-pathological alterations of craniofacial morphology as a result of enhancer deletions supports the notion that enhancers contribute to normal variation in facial shape.

Conclusions

The general shape of the human face and skull, the differences in facial shape between individuals, and the high heritability of facial shape are subjects of broad interest, since they

have far-reaching implications well beyond basic scientific and biomedical considerations. Despite rapid progress in the development of tools for correlating genetic and genomic information with phenotypic traits in human populations, the genetic drivers of variation in craniofacial features remain poorly explored. In this study, we examined the possible impact of distant-acting regulatory sequences on craniofacial morphology. Throughout the genome, we identified several thousand sequences that are likely to be distant-acting enhancers active *in vivo* during mammalian craniofacial development. While this epigenomic analysis was performed in the mouse, the vast majority of these enhancer candidate sequences are conserved between mouse and human. Large-scale characterization of more than 200 candidate sequences in transgenic mice showed the versatility of enhancers in orchestrating gene expression during craniofacial development. These observations are consistent with genome-wide analyses of enhancers active in human neural crest cells, as well as studies of regulatory sequences associated with individual members of the neural crest gene regulatory network (23–27). We also demonstrated that deletion of craniofacial enhancers results in non-pathological, but significant changes in craniofacial morphology in mice. Taken together, these data support that enhancers play a substantial role in determining craniofacial shape. Systematic genome-wide studies of normal morphological variation in human populations are beginning to emerge (15–17) and will offer the opportunity to intersect *in vivo*-derived genome-wide maps of craniofacial enhancers identified in this study with variation data, to gain further mechanistic insight into the molecular underpinnings of human facial shape and variation therein.

Beyond the spectrum of normal morphological variation in craniofacial shape, these results also provide a functional genomic framework for the analysis of craniofacial birth defects. We showed that deletion of craniofacial enhancers results in significant, but non-pathological changes in morphology. Even for Δ hs1431, the enhancer deletion resulting in the most severe reduction in craniofacial gene expression, the morphological phenotype was overall much less severe than the pathological changes observed upon deletion of the *Snai2* gene itself (61). This milder phenotype is not surprising, considering that remaining baseline activity of the gene was observed in all craniofacial structures examined (fig. 6A and fig. S4C). These observations highlight the potential of enhancers to modulate craniofacial morphology in quantitatively subtle ways, without the pathological consequences potentially associated with deleterious protein-coding mutations. These results raise the possibility that sequence or copy number variation affecting more than one enhancer of the same gene may cumulatively result in more severe and potentially pathological phenotypes. Isolated examples of sequence variants in distant-acting enhancers associated with malformations such as clefts of the lip or palate have been described (e.g., (56)) and there is circumstantial evidence that non-coding sequences, including enhancers, play a significant role in these processes (e.g., (35)). There is partial overlap between loci involved in normal facial shape variation and in craniofacial birth defects, supporting the possibility that some dysmorphologies represent the extreme ends of the normal spectrum of variation (15, 16). The improved genome-wide functional annotation of craniofacial *in vivo* enhancers obtained through this study is expected to aid not only in the functional exploration of isolated studies of craniofacial dysmorphologies, but may also facilitate an understanding of the links between normal and pathological variation in craniofacial shape.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

The authors thank Jan Harkes and Mahadev Satyanarayanan for development of the OPT viewer, Shiyi Shen and Harry Hochheiser for integration of the OPT viewer and data sets into FaceBase, Jeff Murray, Mary Marazita, John Manak, Brian Schutte and all FaceBase members for help in the selection of relevant craniofacial intervals and comments on results. A.V. and L.A.P. were supported by NIDCR FaceBase grant U01DE020060 and by NHGRI grants R01HG003988, and U54HG006997. C.A. was supported by a SNSF advanced researcher fellowship. A.S.N. was supported by a F32 NIH/NIGMS NRSA fellowship GM105202. B.H. was supported by NIH R01DE021708, NIH U01DE020054 and NSERC #238992-12 grants. D.R.F. and H.M. were supported by a UK Medical Research Council (MRC) core program grant. B.R. was supported by the Ludwig Institute for Cancer Research and NIH grants U54HG006997 and R01HG003991. Research was conducted at the E.O. Lawrence Berkeley National Laboratory and performed under Department of Energy Contract DE-AC02-05CH11231, University of California. ChIP-seq data is available through GEO (accession number GSE49413) and FaceBase.org. *In vivo* reporter data is available through the Vista Enhancer Browser (<http://enhancer.lbl.gov>) and FaceBase.org. OPT data, including raw images and interactive three-dimensional viewing option is available through FaceBase.org. All enhancer reporter vectors, as well as archived surplus LacZ-stained embryos for selected enhancers, are available from the authors. Craniofacial enhancer knockout lines are available through the Mutant Mouse Regional Resource Centers (Δ hs1431, MMRRC 03895, Δ hs746 MMRRC 03888, Δ hs586 MMRRC 03894).

References and Notes

- Christensen K, Juel K, Herskind AM, Murray JC. *Bmj*. 2004 Jun 12;328:1405. [PubMed: 15145797]
- Wehby GL, Cassell CH. *Oral Dis*. 2010 Jan;16:3. [PubMed: 19656316]
- Kayser M, Schneider PM. *Forensic Sci Int Genet*. 2009 Jun;3:154. [PubMed: 19414162]
- Kohn LAP. *Annu. Rev. Anthropol*. 1991; 20:261.
- Manfredi C, Martina R, Grossi GB, Giuliani M. *Am J Orthod Dentofacial Orthop*. 1997 Jan;111:44. [PubMed: 9009923]
- Johannsdottir B, Thorarinsson F, Thordarson A, Magnusson TE. *Am J Orthod Dentofacial Orthop*. 2005 Feb;127:200. [PubMed: 15750539]
- Satokata I, Maas R. *Nat Genet*. 1994 Apr;6:348. [PubMed: 7914451]
- van den Boogaard MJ, Dorland M, Beemer FA, van Amstel HK. *Nat Genet*. 2000 Apr;24:342. [PubMed: 10742093]
- Kondo S, et al. *Nat Genet*. 2002 Oct;32:285. [PubMed: 12219090]
- Suzuki S, et al. *Am J Hum Genet*. 2009 Mar;84:406. [PubMed: 19249007]
- Dixon MJ. *Hum Mol Genet*. 1996; 5 Spec No:1391. [PubMed: 8875242]
- Ng SB, et al. *Nat Genet*. 2010 Sep;42:790. [PubMed: 20711175]
- Ng SB, et al. *Nat Genet*. 2009 Jan;42:30. [PubMed: 19915526]
- Dixon MJ, Marazita ML, Beaty TH, Murray JC. *Nat Rev Genet*. 2011 Mar;12:167. [PubMed: 21331089]
- Boehringer S, et al. *Eur J Hum Genet*. 2011 Nov;19:1192. [PubMed: 21694738]
- Liu F, et al. *PLoS Genet*. 2012 Sep;8:e1002932. [PubMed: 23028347]
- Paternoster L, et al. *Am J Hum Genet*. 2012 Mar;90:478. [PubMed: 22341974]
- Stern DL. *Evolution*. 2000 Aug;54:1079. [PubMed: 11005278]
- Shen Y, et al. *Nature*. 2012 Aug;488:116. [PubMed: 22763441]
- Zhu J, et al. *Cell*. 2013 Jan;152:642. [PubMed: 23333102]
- Visel A, et al. *Nature*. 2009 Feb;457:854. [PubMed: 19212405]
- Young NM, Chong HJ, Hu D, Hallgrímsson B, Marcucio RS. *Development*. 2010 Oct;137:3405. [PubMed: 20826528]
- Simoës-Costa M, Bronner ME. *Genome Res*. 2013 Jul;23:1069. [PubMed: 23817048]
- Bagheri-Fam S, et al. *Dev Biol*. 2006 Mar;291:382. [PubMed: 16458883]

25. Betancur P, Bronner-Fraser M, Sauka-Spengler T. Proc Natl Acad Sci U S A. 2010 Feb 23;107:3570. [PubMed: 20139305]
26. Simoes-Costa MS, McKeown SJ, Tan-Cabugao J, Sauka-Spengler T, Bronner ME. PLoS Genet. 2012; 8:e1003142. [PubMed: 23284303]
27. Rada-Iglesias A, et al. Cell Stem Cell. 2012 Nov 2;11:633. [PubMed: 22981823]
28. Kaufman, MH. London: Academic Press; 1992.
29. Feng W, et al. PLoS One. 2009; 4:e8066. [PubMed: 20016822]
30. Materials and methods are available as supplementary material on *Science* Online.
31. Blow MJ, et al. Nat Genet. 2010 Sep;42:806. [PubMed: 20729851]
32. Visel A, et al. Cell. 2013 Feb 14;152:895. [PubMed: 23375746]
33. McLean CY, et al. Nat Biotechnol. 2010 May;28:495. [PubMed: 20436461]
34. Mangold E, Ludwig KU, Nothen MM. Trends Mol Med. 2011 Dec;17:725. [PubMed: 21885341]
35. Birnbaum S, et al. Nat Genet. 2009 Apr;41:473. [PubMed: 19270707]
36. Beaty TH, et al. Nat Genet. 2010 Jun;42:525. [PubMed: 20436469]
37. Balczerski B, et al. Dev Biol. 2012 Nov 15;371:203. [PubMed: 23009899]
38. Vaahokari A, Aberg T, Jernvall J, Keranen S, Thesleff I. Mech Dev. 1996 Jan;54:39. [PubMed: 8808404]
39. Koyama E, et al. Dev Dyn. 1996 May;206:59. [PubMed: 9019247]
40. Tucker AS, et al. Development. 1999 Jan;126:221. [PubMed: 9847236]
41. Pennacchio LA, et al. Nature. 2006 Nov 23;444:499. [PubMed: 17086198]
42. Sharpe J, et al. Science. 2002 Apr 19;296:541. [PubMed: 11964482]
43. Heintzman ND, et al. Nature. 2009 May 7;459:108. [PubMed: 19295514]
44. Holland LZ, et al. Genome Res. 2008 Jul;18:1100. [PubMed: 18562680]
45. May D, et al. Nat Genet. 2011 Jan;44:89. [PubMed: 22138689]
46. Visel A, et al. Nat Genet. 2008 Feb;40:158. [PubMed: 18176564]
47. Hochheiser H, et al. Dev Biol. 2011 Jul 15;355:175. [PubMed: 21458441]
48. Alappat S, Zhang ZY, Chen YP. Cell Res. 2003 Dec;13:429. [PubMed: 14728799]
49. Visel A, Rubin EM, Pennacchio LA. Nature. 2009 Sep 10;461:199. [PubMed: 19741700]
50. MacKenzie A, Purdie L, Davidson D, Collinson M, Hill RE. Mech Dev. 1997 Feb;62:29. [PubMed: 9106164]
51. Yokoyama S, et al. Dev Cell. 2009 Dec;17:836. [PubMed: 20059953]
52. Mangold E, et al. Am J Med Genet A. 2009 Dec;149A:2680. [PubMed: 19938073]
53. Nikopensius T, et al. Am J Med Genet A. 2009 Nov;149A:2551. [PubMed: 19839039]
54. Yuan Q, Blanton SH, Hecht JT. Am J Med Genet A. 2011 Jun;155A:1469. [PubMed: 21567910]
55. Leslie EJ, et al. Birth Defects Res A Clin Mol Teratol. 2012 Nov;94:934. [PubMed: 23008150]
56. Rahimov F, et al. Nat Genet. 2008 Nov;40:1341. [PubMed: 18836445]
57. Oram KF, Carver EA, Gridley T. Anat Rec A Discov Mol Cell Evol Biol. 2003 Mar;271:189. [PubMed: 12552634]
58. Mitsiadis TA, Angeli I, James C, Lendahl U, Sharpe PT. Development. 2003 Sep;130:4451. [PubMed: 12900460]
59. Lieberman DE, Hallgrímsson B, Liu W, Parsons TE, Jamniczky HA. J Anat. 2008 Jun;212:720. [PubMed: 18510502]
60. Hallgrímsson B, Lieberman DE, Liu W, Ford-Hutchinson AF, Jirik FR. Evol Dev. 2007 Jan-Feb; 9:76. [PubMed: 17227368]
61. Murray SA, Oram KF, Gridley T. Development. 2007 May;134:1789. [PubMed: 17376812]
62. Li H, Durbin R. Bioinformatics. 2009 Jul 15;25:1754. [PubMed: 19451168]
63. Zhang Y, et al. Genome Biol. 2008; 9:R137. [PubMed: 18798982]
64. Feng J, Liu T, Zhang Y. Chapter 2. Curr Protoc Bioinformatics. 2011 Jun;Unit 2:14. [PubMed: 21633945]
65. Siepel A, et al. Genome Res. 2005 Aug;15:1034. [PubMed: 16024819]

66. Kothary R, et al. *Nature*. 1988 Sep 29.335:435. [PubMed: 3138544]
67. Ahituv N, et al. *PLoS Biol*. 2007 Sep.5:e234. [PubMed: 17803355]
68. Livak KJ, Schmittgen TD. *Methods*. 2001 Dec.25:402. [PubMed: 11846609]
69. Martinez-Abadias N, et al. *Evol Biol*. 2012 Dec.39:554. [PubMed: 23226904]
70. Hallgrímsson B, et al. *Evol Biol*. 2009 Dec.36:355. [PubMed: 23293400]
71. Klingenberg CP. *Mol Ecol Resour*. 2011 Mar.11:353. [PubMed: 21429143]
72. Aybar MJ, Nieto MA, Mayor R. *Development*. 2003 Feb.130:483. [PubMed: 12490555]
73. Nieto MA. *Mech Dev*. 2001 Jul.105:27. [PubMed: 11429279]
74. Jiang R, Lan Y, Norton CR, Sundberg JP, Gridley T. *Dev Biol*. 1998 Jun 15.198:277. [PubMed: 9659933]
75. Cobaleda C, Perez-Caro M, Vicente-Duenas C, Sanchez-Garcia I. *Annu Rev Genet*. 2007; 41:41. [PubMed: 17550342]
76. Sanchez-Martin M, et al. *Hum Mol Genet*. 2002 Dec 1.11:3231. [PubMed: 12444107]
77. Hill RE, et al. *Genes Dev*. 1989 Jan.3:26. [PubMed: 2565278]
78. Robert B, Sassoon D, Jacq B, Gehring W, Buckingham M. *Embo J*. 1989 Jan.8:91. [PubMed: 2565810]
79. Catron KM, et al. *Mol Cell Biol*. 1995 Feb.15:861. [PubMed: 7823952]
80. Blin-Wakkach C, et al. *Proc Natl Acad Sci U S A*. 2001 Jun 19.98:7336. [PubMed: 11390985]
81. Mackenzie A, Leeming GL, Jowett AK, Ferguson MW, Sharpe PT. *Development*. 1991 Feb. 111:269. [PubMed: 1680043]
82. Houzelstein D, Cohen A, Buckingham ME, Robert B. *Mech Dev*. 1997 Jul.65:123. [PubMed: 9256350]
83. Vastardis H, Karimbux N, Guthua SW, Seidman JG, Seidman CE. *Nat Genet*. 1996 Aug.13:417. [PubMed: 8696335]
84. Jumlongras D, et al. *Am J Hum Genet*. 2001 Jul.69:67. [PubMed: 11369996]
85. Jezewski PA, et al. *J Med Genet*. 2003 Jun.40:399. [PubMed: 12807959]
86. Tsuchida T, et al. *Cell*. 1994 Dec 16.79:957. [PubMed: 7528105]
87. Laugwitz KL, et al. *Nature*. 2005 Feb 10.433:647. [PubMed: 15703750]
88. Ahlgren U, Pfaff SL, Jessell TM, Edlund T, Edlund H. *Nature*. 1997 Jan 16.385:257. [PubMed: 9000074]
89. Sheng HZ, et al. *Science*. 1997 Dec 5.278:1809. [PubMed: 9388186]
90. Pfaff SL, Mendelsohn M, Stewart CL, Edlund T, Jessell TM. *Cell*. 1996 Jan 26.84:309. [PubMed: 8565076]
91. Hindorff LA, et al. *Proc Natl Acad Sci U S A*. 2009 Jun 9.106:9362. [PubMed: 19474294]




Fig. 1. Study Overview

P300 ChIP-seq was performed on whole mouse face tissue from e11.5 embryos, which identified 4,399 putative distant-acting craniofacial enhancers. More than 200 craniofacial candidate enhancers were characterized in depth through LacZ transgenesis in mouse embryos (LacZ panel), and selected enhancers were further analyzed by optical projection tomography (OPT panel; unstained tissue is shown in green, LacZ stained tissue is shown in red). Furthermore, a panel of three enhancers near functionally unrelated genes was studied by knockout analysis and detailed skull morphometry in mice.




Fig. 2. Genome-wide identification of candidate craniofacial enhancers
 Mouse genome graph showing all p300-enriched regions (green dots) and all 281 sequences tested *in vivo* or re-examined for craniofacial activity in this study (red dots). Examples of selected major craniofacial genes (34) and genomic regions (e.g., 8q24 (35), *ABCA4* (36)) are highlighted by pink boxes. Known craniofacial loci were generally enriched in candidate sequences and were specifically targeted for sampling in transgenic assays (red dots). The three genomic regions studied by knockout analysis are highlighted by blue boxes.




Fig. 3. Transgenic characterization of craniofacial candidate enhancers results in the identification of facial substructure-specific enhancers

(A) Selection of 18 reproducible craniofacial enhancers at e11.5 illustrates the broad spectrum of activity patterns observed *in vivo*. For each tested candidate enhancer, one representative embryo face is shown, the reproducibility of each pattern among multiple transgenic founder embryos is indicated at the right bottom corner of each image. For each element, the nearest relevant craniofacial gene, if any, is also provided. Additional embryo images obtained with each enhancer construct can be viewed at <http://enhancer.lbl.gov> or <http://facebase.org>. (B) Upper panel: Four examples of highly restricted specificity to craniofacial substructures (see **main text**). Lower panel: Four examples of internal enhancer activity captured by OPT scanning of LacZ stained embryos. Green: no LacZ activity (enhancer inactive), red: LacZ activity (enhancer active). A, anterior; D, dorsal; fb, forebrain; lnp, lateral nasal prominence; mble, mandibular process; mnp, medial nasal prominence; mx, maxillary process; P, posterior; V, ventral.




Fig. 4. Regulatory landscapes of craniofacial loci

(A) Craniofacial enhancers near *Msx1*, a major craniofacial gene, were identified by p300 ChIP-seq (green boxes). This included the re-identification of a region proximal to *Msx1* with previously described enhancer activity (mm426, (50)), as well as four additional, more distal enhancers with complementary activity patterns. For each enhancer, only one representative embryo is shown, numbers indicate reproducibility. Red arrows indicate selected correlations between *Msx1* RNA expression (ISH) and individual enhancers (see **main text**). Red box indicates enhancer hs746 which was further studied by knockout

analysis. *Msx1* ISH: Embryos database (<http://embryos.jp>) (51). **(B)** Identification of craniofacial enhancers in the cleft- and morphology-associated gene desert at human chromosome 8q24 (orthologous mouse region shown, (35)). Brown box indicates the region corresponding to a 640kb human region associated with orofacial clefts (non-syndromic cleft lip with or without cleft palate, NSCL/P) and devoid of protein-coding genes. Two of four candidate enhancers within the region drove craniofacial expression. For each enhancer, lateral and frontal views of one representative embryo are shown. **(C)** Identification of a craniofacial midline enhancer at the cleft-associated susceptibility interval at the *ABCA4* locus (36). The enhancer is highly active in the nasal prominences (yellow arrows), but not the maxillary or mandible (pink arrows).




Fig. 5. Developmental activity patterns of three enhancers selected for deletion studies
 The *in vivo* activity of each enhancer was monitored at different stages of development (e11.5, e13.5 and e15.5). All enhancers were reproducibly active in the craniofacial complex during embryonic development, with spatial changes in activity across stages. Side views, LacZ-stained whole-mount embryos. Front views, optical projection tomography reconstructed 3D images. Regions of enhancer activity are shown in red. Also see movies S1–S9.




Fig. 6. Expression phenotypes resulting from craniofacial enhancer deletions
 (A, B) *In vivo* activity pattern of hs1431 (at e11.5) and hs746 (at e13.5). OPT data is represented in red (LacZ, enhancer active) and green (no LacZ, enhancer inactive). (C, D) Expression levels of enhancer target genes in craniofacial tissues dissected from wild-type (gray) and knockout (red) littermate embryos. Error bars show the variation among individuals of the same genotype (SEM). *, $P < 0.05$ (Student T-test, 1-tailed); Mble, mandibular; Mx, maxillary; MNP, medial nasal process; LNP, lateral nasal process.




Fig. 7. Enhancer deletions cause changes of craniofacial morphology

(A) Canonical variate analysis (CVA) of micro-CT data from mice with three different enhancer deletions, compared to wild-type. The 3D morphs show the morphological variation that corresponds to the first three canonical variates. Renderings show CV endpoints 3× expanded to improve visualization. (B) Magnitude of shape differences between wild-type and enhancer null mice, based on Procrustes distances (30). Error bars indicate standard deviation of shape differences from resampling Procrustes distances across 10,000 iterations. (C) Wireframe visualization of the first three canonical variates, which are predominantly driven by morphological differences between wild-type mice and Δhs1431, Δhs746 and Δhs586, respectively. CV endpoints are superimposed as red and blue wireframes, respectively.

Table 1
Top enriched annotations of mouse and human phenotypes associated with candidate craniofacial enhancers

Top: Ten of the twelve most significantly enriched terms from the Mouse Phenotype ontology directly relate to craniofacial development. The remaining two phenotypes (abnormal axial skeleton morphology and abnormal skeleton development, not shown) relate to general skeleton development, a process that shares key signaling pathways with cranial skeleton development (37). Bottom: Six of the ten most significantly enriched terms from the Human Phenotype ontology are relevant to craniofacial development. The four remaining phenotypes (not shown) are all associated with limb abnormalities, consistent with previous knowledge of shared developmental pathways during limb and face development (38–40). In each analysis, only terms exceeding 2-fold binomial enrichment were considered and ranked by P-value (binomial raw P-values).

Rank	Phenotype Term	Binomial P-value	Binomial Fold Enrichment
<i>Mouse phenotypes</i>			
1	abnormal craniofacial morphology	5.8e-110	2.0
3	abnormal head morphology	1.7e-88	2.1
4	abnormal craniofacial development	3.8e-82	2.4
5	abnormal craniofacial bone morphology	1.3e-78	2.1
6	abnormal facial morphology	5.5e-78	2.2
7	abnormal cranium morphology	3.1e-77	2.2
9	abnormal mouth morphology	3.5e-72	2.3
10	abnormal orofacial morphology	1.5e-71	2.3
11	abnormal viscerocranium morphology	1.0e-62	2.3
12	abnormal neurocranium morphology	2.1e-60	2.5
<i>Human phenotypes</i>			
2	malar hypoplasia	3.6e-17	2.4
3	abnormality of the midface	7.6e-17	2.3
5	abnormal location of ears	5.7e-16	2.1
7	low-set ears	1.1e-15	2.1
8	abnormality of the fontanelles and cranial sutures	1.2e-15	2.2
9	abnormality of the calvarium	1.3e-15	2.1